Stock of the Day

Cencora (COR)

$323.63

+$1.60 (+0.5%)

Market Cap: $61.45B

About Cencora

Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.

Cencora Bull Case

Here are some ways that investors could benefit from investing in Cencora, Inc.:

• The company recently reported earnings per share (EPS) of $4.48, exceeding analysts' expectations, indicating strong financial performance.
• Cencora, Inc. has initiated a significant share buyback program, allowing for the repurchase of $2.00 billion in shares, which often signals that the company believes its stock is undervalued.
• The current stock price is around $305, which may present a buying opportunity for investors looking for growth in the healthcare sector.
• With a return on equity of 125.45%, Cencora, Inc. demonstrates effective management and profitability, which can attract investors seeking high returns.
• The company has declared a quarterly dividend of $0.60 per share, providing a steady income stream for investors, with an annualized yield of 0.7%.

Cencora Bear Case

Investors should be bearish about investing in Cencora, Inc. for these reasons:

• The company has a high debt-to-equity ratio of 3.53, which may indicate financial risk and could affect its ability to manage debt obligations effectively.
• Cencora, Inc. has a relatively low net margin of 0.79%, suggesting that profit generation from revenue is limited, which could impact long-term growth potential.
• The current market conditions and economic uncertainties may pose challenges for the healthcare sector, potentially affecting Cencora, Inc.'s performance.
• With a price-to-earnings (PE) ratio of 24.36, the stock may be considered overvalued compared to its earnings, which could deter value-focused investors.
• The company's beta of 0.57 indicates lower volatility compared to the market, which may not appeal to investors seeking high-risk, high-reward opportunities.

Recent News

• Cencora (NYSE:COR) EVP Sells 11,300 Shares (insidertrades.com)